electroCore, Inc. Announces The Launch of a New Online Shop in the United Kingdom
15 Dezembro 2021 - 10:00AM
electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a
commercial-stage bioelectronic medicine company, today
announced the launch of an e-commerce shop for patients residing in
the United Kingdom. The site, which can be found at
www.gammacore.co.uk, requires patients to complete a healthcare
questionnaire in order to purchase a gammaCore Sapphire™,
non-invasive vagus nerve stimulator (nVNS) device online.
The first product launched on the platform is
designed to treat menstrual migraine, supporting the 60% of women
who report migraine symptoms associated with their menstrual cycle.
This platform will allow patients to experience a fully virtual
experience by completing an online clinical assessment, having
product delivered to their door, and being trained via video calls
with a member of the UK customer service team.
“We want to make gammaCore more accessible to
patients looking to better manage their primary headache
conditions. With an estimated 70% of migraineurs being female, the
specificity of menstrual migraine is a natural starting point in a
new chapter for our business within the online market. We
have created a simple assessment process with full clinician
oversight offering ongoing customer care as required,”
stated Karly Hoggard, Director of Global Commercial
Development at electroCore. “Many women suffering from migraine
symptoms each month expect to live with such symptoms, impacting
daily life, work, family and social commitments. We are excited to
offer a clinically proven option women looking for solutions to
treat their primary headaches, and through this platform we hope to
empower people to take ownership of their conditions and regain
control.”
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic medicine company dedicated to
improving patient outcomes through its non-invasive vagus nerve
stimulation therapy platform, initially focused on the treatment of
multiple conditions in neurology. The company's current indications
are the preventive treatment of cluster headache and migraine, the
acute treatment of migraine and episodic cluster headache, the
acute and preventive treatment of migraines in adolescents, and
paroxysmal hemicrania and hemicrania continua in adults.
For more information, visit www.electrocore.com.
About gammaCoreTMgammaCoreTM (nVNS) is the
first non-invasive, hand-held medical therapy applied at the neck
as an adjunctive therapy to treat migraine and cluster headache
through the utilization of a mild electrical stimulation to the
vagus nerve that passes through the skin. Designed as a portable,
easy-to-use technology, gammaCore can be self-administered by
patients, as needed, without the potential side effects associated
with commonly prescribed drugs. When placed on a patient’s neck
over the vagus nerve, gammaCore stimulates the nerve’s afferent
fibers, which may lead to a reduction of pain in patients.
gammaCore (nVNS) is FDA cleared in the United States for
adjunctive use for the preventive treatment of cluster headache in
adult patients, the acute treatment of pain associated with
episodic cluster headache in adult patients, and the acute and
preventive treatment of migraine in adolescent (ages 12 and older)
and adult patients. gammaCore is CE-marked in the European Union
for the acute and/or prophylactic treatment of primary headache
(Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and
Hemicrania Continua) and Medication Overuse Headache in adults.
gammaCore is contraindicated for patients if they:
- Have an active implantable medical device, such as a pacemaker,
hearing aid implant, or any implanted electronic device
- Have a metallic device, such as a stent, bone plate, or bone
screw, implanted at or near the neck
- Are using another device at the same time (e.g., TENS Unit,
muscle stimulator) or any portable electronic device (e.g., mobile
phone)
Safety and efficacy of gammaCore have not been evaluated in the
following patients:
- Adolescent patients with congenital cardiac issues
- Patients diagnosed with narrowing of the arteries (carotid
atherosclerosis)
- Patients who have had surgery to cut the vagus nerve in the
neck (cervical vagotomy)
- Pediatric patients (less than 12 years)
- Pregnant women
- Patients with clinically significant hypertension, hypotension,
bradycardia, or tachycardia
Please refer to the gammaCore Instructions for Use for all of
the important warnings and precautions before using or prescribing
this product.
For more information, please visit www.gammacore.co.uk.
Forward-Looking Statements
This press release and other written and oral statements made by
representatives of electroCore may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include, but
are not limited to, statements about electroCore's business
prospects and clinical and product development plans; its pipeline
or potential markets for its technologies; the timing, outcome and
impact of regulatory, clinical and commercial developments; the
Company’s business prospects in the UK (including its e-commerce
initiative) and other new markets and other statements that are not
historical in nature, particularly those that utilize terminology
such as "anticipates," "will," "expects," "believes," "intends,"
other words of similar meaning, derivations of such words and the
use of future dates. Actual results could differ from those
projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the ability to raise
the additional funding needed to continue to pursue electroCore’s
business and product development plans, the inherent uncertainties
associated with developing new products or technologies, the
ability to commercialize gammaCore™, the potential impact and
effects of COVID-19 on the business of electroCore, electroCore’s
results of operations and financial performance, and any measures
electroCore has and may take in response to COVID-19 and any
expectations electroCore may have with respect thereto, competition
in the industry in which electroCore operates and overall market
conditions. Any forward-looking statements are made as of the date
of this press release, and electroCore assumes no obligation to
update the forward-looking statements or to update the reasons why
actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents electroCore files with the SEC available at
www.sec.gov.
Investors:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital
or
Media Contact:
Jackie Dorsky
electroCore
908-313-6331
Jackie.dorsky@electrocore.com
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024